ライフサイエンスコーパス: hypomania

1 pecific adverse effects were observed (e.g., hypomania).

2 ions remained, except for working memory and hypomania.

3 ecurrent episodes of depression and mania or hypomania.

4 ncreased risk of treatment-emergent mania or hypomania.

5 , and can be associated with impulsivity and hypomania.

6 , remission, and treatment-emergent mania or hypomania.

7 ons for individuals with or at risk of mania/hypomania.

8 the DSM-5 as cardinal symptoms of mania and hypomania.

9 ng placebo discontinued treatment because of hypomania.

10 ajor depression predicted new-onset mania or hypomania.

11 major depression and in episodes of mania or hypomania.

12 h antidepressant treatment-emergent mania or hypomania.

13 h fewer symptoms than required for threshold hypomania.

14 ure to evaluate the workplace costs of mania/hypomania.

15 n would alter the prevalence of mania and/or hypomania.

16 pomanic symptoms, 57% met criteria for mixed hypomania.

17 preceding shifts from depression to mania or hypomania.

18 icantly higher rate of switching to mania or hypomania.

19 eported cases of treatment-emergent mania or hypomania (0.88 [0.62-1.13]; GRADE=moderate).

20 ncreased risk of treatment-emergent mania or hypomania (0.926 [0.576-1.491], p=0.753), but 52 week ex

21 cantly higher rates of subthreshold mania or hypomania (13.3% compared with 1.2%), manic, mixed, or h

22 ips were specific to depression versus mania/hypomania; (3) whether findings in a first, "discovery"

23 re 7 episodes of treatment-emergent mania or hypomania, 5 occurring in the combined treatment group.

24 We further attempted to predict hypomania, a VCVS DBS complication.

25 dicted OCD response, depression response, or hypomania above chance.

26 dverse events included transient symptoms of hypomania, agitation, impulsivity, and sleeping disorder

27 and mania has been well established, that of hypomania and bipolar II (BPII) disorder has not.

28 to guide and monitor interventions for mania/hypomania and depression in at-risk individuals.

29 ified neural variables associated with mania/hypomania and depression risk; multivariable regression

30 treatment and prevention of recurrent mania/hypomania and depression that characterize bipolar disor

31 e do not support the splitting between mania/hypomania and depression); family history, major depress

32 pathophysiological processes associated with hypomania and depression, along with the particular impa

33 liably associated with greater risk of mania/hypomania and depression, respectively.

34 s associated with greater risk of both mania/hypomania and depression.

35 th extreme mood swings that include mania or hypomania and depression.

36 .41; 95% CI, 0.03-0.75) correlations between hypomania and diagnosed bipolar disorder were found.

37 Threshold switches into full-duration hypomania and mania occurred in 11.4% and 7.9%, respecti

38 ty were observed for family history of mania/hypomania and multiple past mood episodes.

39 mania is common in patients with symptoms of hypomania and particularly common in women.

40 Associations between hypomania and polygenic risk scores for bipolar disorder

41 er, type I, was admitted to the hospital for hypomania and poorly controlled diabetes mellitus.

42 ixed symptoms increased with the severity of hypomania and then decreased at the most severe levels o

43 p between spectrum (dimensional) measures of hypomania and white matter microstructure across those i

44 [at least 1 but <7 days] or recurrent brief hypomania) and threshold switches (emergence of full-dur

45 ve iTBS participant had a treatment emergent hypomania, and a second episode occurred during open-lab

46 rtum period, with a focus on managing mania, hypomania, and the psychotic components of the illness.

47 nical remission, treatment-emergent mania or hypomania, and tolerability (using dropout rates as a pr

48 rs, depressive disorders, anxiety disorders, hypomania, and, as a measure of insulin resistance, Home

49 Depression, mania or hypomania, anxiety, and functioning were measured using

50 Taking vulnerability to hypomania as a surrogate model of impulsivity, we utiliz

51 hiatric complications (suicidal attenuation, hypomania) as well as high costs.

52 s who converted did not have any symptoms of hypomania at baseline.

53 patients to demonstrate subsequent mania or hypomania at follow-up.

54 esults indicate steeper delay discounting in hypomania at multiple stages of information processing.

55 hreshold brief hypomania (emergence of brief hypomania [at least 1 but <7 days] or recurrent brief hy

56 01), anxiety (B = - 6.77, p <= 0.001), mania/hypomania (B = - 6.47, p <= 0.001); and positive relatio

57 0.002), anxiety (B = 4.68, p = 0.002), mania/hypomania (B = 6.08, p <= 0.001); negative relationships

58 al anger was inversely associated with mania/hypomania (beta = -2.08, p = 0.018).

59 e more pronounced in BDII than BDI (mania or hypomania: beta = 0.16 [95% CrI, 0.02-0.30]; workplace f

60 s) are episodes of mania (bipolar I, BPI) or hypomania (bipolar II, BPII) interspersed with periods o

61 sion, but without a prior diagnosis of mania/hypomania, bipolar disorder, or psychosis or treatment w

62 ound no evidence of treatment-emergent mania/hypomania by 12 weeks in children and adolescents.

63 were the most important predictors of mania/hypomania by 12 weeks.

64 Although mania and hypomania define bipolar disorder, depressive episodes a

65 lness defined by recurrent episodes of mania/hypomania, depression and circadian rhythm abnormalities

66 hosis to mood disturbance, duration of mania/hypomania, depression, and psychosis) and 10-year outcom

67 ne episode of deep-brain-stimulation-induced hypomania during the blinded on-stimulation period); all

68 e likely than men to experience subthreshold hypomania during visits with depression (40.7% compared

69 rgent affective switch (a switch to mania or hypomania early in the course of treatment) were also ex

70 nse and the occurrence of subthreshold brief hypomania (emergence of brief hypomania [at least 1 but

71 Symptoms of hypomania, even when of low intensity, were frequently a

72 hosis predicted more weeks ill with mania or hypomania (F(1,80) = 12.2, P =.0008).

73 he hypomania-prone group relative to the low hypomania group, indicative of greater reward responsive

74 reshold switches (emergence of full-duration hypomania [> or =7 days] or mania) were blindly assessed

75 inician-rated depression, anxiety, and mania/hypomania; H2:the neuroticism factor and its subfactors

76 The hypomania heritability estimate was 59% (95% CI, 52%-64%

77 (HR = 1.713; 95% CI, 1.373-2.137; P < .001), hypomania (HR = 4.502; 95% CI, 3.466-5.849; P < .001), o

78 order; depression more common than mania and hypomania in bipolar disorders; trait mood lability in m

79 oms in major depressive disorder; factors of hypomania inside major depressive disorder; recurrent co

80 is characterized by episodes of mania and/or hypomania interspersed with periods of depression.

81 Our findings indicate that proneness to hypomania is associated with both reward hypersensitivit

82 Hypomania is associated with impulsive decision making a

83 Mixed hypomania is common in patients with symptoms of hypoman

84 Mania/hypomania is the pathognomonic feature of bipolar disord

85 major concern is the risk for mood switch to hypomania, mania, and mixed states.

86 ale scores, and the patients presenting with hypomania, mania, or a mixed state exhibited a 74% decre

87 and mood symptoms and states (depression and hypomania/mania).

88 that manic symptoms below the threshold for hypomania (mixed features) are common in individuals wit

89 ieved recovery, time to recurrence of mania, hypomania, mixed state, or a depressive episode was exam

90 nd those who had treatment-emergent mania or hypomania (N=46).

91 xperienced a switch during the study period (hypomania, N=17; severe hypomania, N=3).

92 ng the study period (hypomania, N=17; severe hypomania, N=3).

93 ionship between left ITG thickness and mania/hypomania; NEO vulnerability mediated the relationship b

94 Hypomania of long or short duration in BP-II seems to be

95 tes (mixed depression) and dysphoric (mixed) hypomania (opposite polarity symptoms in the same episod

96 Diagnosis of mania/hypomania or initiation of mood stabilizer therapy.

97 ar depression (BPD), 30 with current bipolar hypomania or mania (BPM), 15 bipolar euthymic (BPE), and

98 ference between groups in treatment-emergent hypomania or mania (six patients in the modafinil group

99 tive risks of switches in mood polarity into hypomania or mania during acute and continuation trials

100 risks of threshold switches to full-duration hypomania or mania in both acute and long-term continuat

101 The intermediate phenotypes include 1) hypomania or mania not otherwise specified, in which the

102 pomanic symptoms at baseline with subsequent hypomania or mania was determined in survival analyses u

103 The hallmark of bipolar disorder is hypomania or mania, and the predominant phase of illness

104 n 1 and 3 days in duration, and 2) irritable hypomania or mania, in which the patient has demarcated

105 meet the full DSM-IV diagnostic criteria for hypomania or mania, including the duration criterion, an

106 the presence of symptoms of depression or of hypomania or mania, measured by the Inventory of Depress

107 ntimanic medication (excluding patients with hypomania or mania, mixed symptoms, or rapid cycling).

108 sis, 19.6% (N=108) of the sample experienced hypomania or mania, resulting in revision of diagnoses f

109 onitor course of illness and to identify any hypomania or mania.

110 then decreased at the most severe levels of hypomania or mania.

111 18.7) and MDEs (OR=2.0, CI: 1.5-2.7) but not hypomania (OR=1.3, CI: 0.5-3.6).

112 n was significantly greater for women during hypomania (P<.001).

113 The hypomania-prone group also showed smaller FRN to losses,

114 In the second experiment, the hypomania-prone group evidenced greater differentiation

115 In the first experiment, the hypomania-prone group made significantly more immediate

116 icted, rewards elicited a smaller FRN in the hypomania-prone group relative to the low hypomania grou

117 ty to both reward and punishment outcomes in hypomania-prone individuals not receiving pharmacotherap

118 dimensional model of bipolar disorder, with hypomania representing a continuous trait underlying the

119 eft vlPFC activity was associated with mania/hypomania risk and attenuated by MDD history.

120 -Report (MOODS-SR-L) assessed lifetime mania/hypomania risk and depression risk.

121 Spectrum Self-Report assessed lifetime mania/hypomania risk and depression risk.

122 er (MDD), replicable neural markers of mania/hypomania risk are needed for earlier BD diagnosis and p

123 ses underlying lifetime depression and mania/hypomania risk can provide biologically informed targets

124 in score divided the new sample into 3 mania/hypomania risk groups.

125 lifetime depression risk and lifetime mania/hypomania risk in all three samples (all ps< 0.05 qFDR).

126 arly interventions for, depression and mania/hypomania risk in young adults.

127 shed, reliable neural markers denoting mania/hypomania risk to help with early risk detection and dia

128 ty, showed a positive association with mania/hypomania risk, which remained after excluding individua

129 s with MDD history and was specific to mania/hypomania risk.

130 main score to determine specificity to mania/hypomania risk.

131 tivity were positively associated with mania/hypomania risk: discovery omnibus chi2 = 1671.7 (P < .00

132 e networks and lifetime depression and mania/hypomania risk; (2) the extent to which these relationsh

133 fetime depression risk versus lifetime mania/hypomania risk; (3) whether findings in a first, Discove

134 Patients with subthreshold hypomania (SBP; subthreshold bipolar disorder) were indi

135 ates were fairly consistent across different hypomania severity groups.

136 on at up to 12 months post scan and/or mania/hypomania severity in (n = 61, including participants fr

137 Duration of mania/hypomania showed 2 discontinuities demarcating 3 groups:

138 romising neural markers distinguishing mania/hypomania-specific risk from depression-specific risk an

139 nxiety disorder (GAD), panic disorder, mania/hypomania, substance use disorder, suicidal ideation, an

140 emory at age 10 years with decreased risk of hypomania symptoms at ages 22 to 23 years (aOR, 0.694; 9

141 der rather than to stronger effects of mania/hypomania than depression.

142 were significantly more likely to experience hypomania than those with bipolar II disorder.

143 ho underwent sleep restriction reported mild hypomania that was unrelated to weekly sleep duration.

144 56.9% +/- 28.8% of total weeks with mania or hypomania (unipolar or mixed), and 38.7% +/- 28.8% of th

145 tuent episodes (major depression, mania, and hypomania) using interview and best-estimate diagnostic

146 s accounted for 41% (95% CI, 36%-47%) of the hypomania variance in male individuals and 45% (95% CI,

147 Proneness to hypomania was also associated with greater N1 amplitude

148 Mixed hypomania was defined at a given visit as a Young Mania

149 on were examined at ages 17 to 18 years, and hypomania was examined at ages 22 to 23 years.

150 Higher heritability for hypomania was found for male compared with female indivi

151 primary symptom, the prevalence of mania and hypomania was reduced.

152 t that recurrent major depression as well as hypomania was required for a diagnosis of BPII disorder.

153 Hypomania was significantly associated with the polygeni

154 of threshold switches to subthreshold brief hypomanias was higher in both the acute (ratio=3.60) and

155 of brief (2-6 days) vs longer (> or =7 days) hypomanias were not significantly different on any measu

156 t characteristics were associated with mania/hypomania, which warrants clinical attention.

157 ad developed one or more distinct periods of hypomania, while another 19% had at least one episode of

158 MAIN OUTCOME MEASURES: Mania/hypomania with or without depression among those who met

159 Subthreshold BPD was defined as recurrent hypomania without a major depressive episode or with few